[1] Lakmie SG, Harinda R, Nicholas S, et al. Cirrhotic portal hypertension: from pathophysiology to novel therapeutics[J].World J Gastroenterol, 2020, 26(40):6111-6140. DOI:10.3748/wjg.v26.i40.6111.
[2] Agustín A, Rafael B, Virginia HG. Portal hypertension:recommendations for diagnosis and treatment. Consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Centre for Liver and Digestive Diseases (CIBERehd) [J].Gastroenterol Hepatol, 2025, 48(1):502208. DOI: 10.1016/j.gastrohep.2024.502208.
[3] Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension[J]. World J Gastroenterol, 2014, 20(15):4300-4315. DOI: 10.3748/wjg.v20.i15.4300.
[4] 中华医学会外科学分会脾及门静脉高压外科学组 . 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2025 版)[J]. 中华消化外科杂志, 2025, 24(3): 271-280. DOI:10.3760/cma.j.cn115610-20241228-00590.
[5] Kaplan DE, Ripoll C, Thiele M, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis[J]. Hepatology, 2024,79(5):1180-1211. DOI: 10.1097/HEP.0000000000000647.
[6] Wang P, Hu XH, Xie F. Predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis[J]. Peer J, 2023, 11(0): e15956.DOI:10.7717/peerj.15956.
[7] Xu X, Ding H, You H, et al. Chinese guidelines for clinical diagnosis, treatment, and management of cirrhosis[J]. J Clin Transl Hepatol, 2026, 14(1):96-115. DOI: 10.14218/JCTH.2025.00517.
[8] Brown RS, Brown KA, Flamm S, et al. Screening and management of portal hypertension and varices in cirrhosis:Expert perspectives[J]. Hepatol Commun, 2025, 9(4): e0682.DOI:10.1097/HC9.0000000000000682.
[9] 韩一凡, 徐小元 . 2025 年肝纤维化、肝硬化、门静脉高压临床研究进展 [J]. 中华肝脏病杂志, 2026, 34(1): 7-9. DOI:10.3760/cma.j.cn501113-20251205-00517.
[10] You H, Maiwall R, Chen J, et al. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update[J/OL]. Hepatol Int, 2026(2026-06-27)[2026-07-07]. https://pubmed. ncbi. nlm. nih. gov/42365189/.DOI: 10.1007/s12072-026-11108-1.[published online ahead of print]
[11] Jang ES, Heo NY; Korean Association for the Study of the Liver (KASL). 2025 KASL clinical practice guidelines for management of hepatitis C[J]. Clin Mol Hepatol, 2026, 32(1):1-52. DOI: 10.3350/cmh.2025.0777.
[12] Eslam M, Fan JG, Yu ML, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease[J]. Hepatol Int, 2025, 19(2):261-301. DOI:10.1007/s12072-024-10774-3.
[13] Dermot G, Rosemary B, Ann B, et al. British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis[J]. Gut, 2025, 74(9):1364-1409. DOI:10.1136/gutjnl-2024-333171.
[14] Sheena B, Aalam S, Kris VK. Primary biliary cholangitis and primary sclerosing cholangitis therapy landscape[J]. Am J Gastroenterol, 2025, 120(1):151-158. DOI: 10.14309/ajg.0000000000003174.
[15] Roberto JG, Guadalupe GT, Jaime B, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J].N Engl J Med, 2005, 353(21):2254-2261. DOI: 10.1056/NEJMoa044456.
[16] Ripoll C. Hepatic venous pressure gradient and outcomes in cirrhosis[J]. J Clin Gastroenterol, 2007, 41 Suppl 3:S330-335.DOI: 10.1097/MCG.0b013e318150d0f4.
[17] Ian AR, Càndid V, Jessica ES, et al. Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: a bayesian reanalysis of the PREDESCI trial[J]. Hepatology, 2023, 78(2):530-539. DOI: 10.1097/HEP.0000000000000342.
[18] Thomas R, Mattias MJJH. Beta adrenergic blockade and decompensated cirrhosis[J]. J Hepatol, 2017, 66(4): 849-859.DOI: 10.1016/j.jhep.2016.11.001.
[19] Sheng JY, Meng ZF, Li Q, et al. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension[J]. Hepatobil Panc Dis Int, 2024, 23(1):4-13. DOI: 10.1016/j.hbpd.2023.08.003.
[20] Marina S, David EK, Tamar HT, et al. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: a national cohort study[J]. Hepatology, 2023, 77(2):489-500.DOI: 10.1002/hep.32737.
[21] 杨雨霏, 王俊俊, 陆伦根, 等 . 肝硬化临床治疗争议与进展:从门静脉高压管理到并发症防治的循证医学视角[J]. 中华肝脏病杂志 , 2025, 33(8):734-737. DOI: 10.3760/cma. j.cn501113-20250319-00101.
[22] Sarah S, Saro K, John JK, et al. Randomized trial of 1-week versus 2-week intervals for endoscopic ligation in the treatment of patients with esophageal variceal bleeding[J].Hepatology, 2016, 64(2):549-555. DOI:10.1002/hep.28597.
[23] Hiroshi Y, Yasuhiro M, Nobuhiko T, et al. A randomized control trial of bi-monthly versus bi-weekly endoscopic variceal ligation of esophageal varices[J]. Am J Gastroenterol, 2005, 100(9):2005-2009. DOI:10.1111/j.1572-0241.2005.41864.x.
[24] Alberto F, Alberto Z, Giacomo G, et al. Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension[J]. World J Hepatol, 2016, 8(24):1012-1018. DOI:10.4254/wjh.v8.i24.1012.
[25] Yang T, Chong Z, Linhao Z, et al. Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress[J]. J Cell Mol Med, 2021, 25(22):10389-10402. DOI:10.1111/jcmm.16968.
[26] Odutayo A, Desborough MJR, Trivella M, et al. Restrictive versus liberal blood transfusion for gastrointestinal bleeding: a systematic review and meta-analysis of randomised controlled trials[J]. Lancet Gastroenterol Hepatol, 2017, 2(5):354-360.DOI:10.1016/S2468-1253(17)30054-7.
[27] Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage[J]. Hepatology,2014, 60(3):954-963. DOI:10.1002/hep.27006.
[28] Xiaoyuan X, Chengwei T, Huiguo D, et al. Guidelines for the management of esophagogastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Transl Hepatol, 2023, 11(7):1565-1579. DOI:10.14218/JCTH.2023.00061.
[29] 吕勇, 韩国宏, 樊代明 . 肝硬化急性静脉曲张出血的治疗现状 [J]. 中华 肝 脏 病 杂 志 , 2024, 32(11):1037-1041. DOI:10.3760/cma.j.cn501113-20240306-00113.
[30] Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila F, et al. Meta-analysis: antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding - an updated cochrane review[J]. Aliment Pharmacol Ther, 2011, 34(5):509-518.DOI:10.1111/j.1365-2036.2011.04746.x.
[31] Li XH, Wang J, Li Q, et al. Endoscopic management of acute esophagogastric variceal bleeding: recent advances[J]. Ther Adv Gastroenterol, 2026, 19:17562848251414043. DOI:10.1177/17562848251414043.
[32] Saeed ZA, Stiegmann GV, Ramirez FC, et al. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: a multicenter prospective randomized trial[J]. Hepatology, 1997, 25(1):71-74. DOI:10.1002/hep.510250113.
[33] 中华医学会消化病学分会微创介入协作组 . 经颈静脉肝内门体分流术治疗门静脉高压专家共识[J]. 中华肝脏病杂志, 2022, 30(12):1349-1364. DOI: 10.3760/cma.j.cn501113-20221109-00553.
[34] Cosmas RA, Lesmana, Akash S, et al. Management of acute variceal bleeding: updated APASL guidelines[J]. Hepatol Int,2025, 19(5):1003-1031. DOI:10.1007/s12072-025-10894-4.
[35] European Association for the Study of the Liver. EASL clinical practice guidelines on TIPS[J]. J Hepatol, 2025, 83(1):177-210. DOI:10.1016/j.jhep.2025.01.029.
[36] Mamadou LS, Samuel JM, Hassan A, et al. Transjugular intrahepatic portosystemic shunt: advanced techniques and complications[J]. Tech Vasc Interv Radiol, 2025, 28(3):101056. DOI:10.1016/j.tvir.2025.101056.
[37] Conthe A, Ibañez-Samaniego L, Calleja E, et al. Feasibility,safety and efficacy of transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis[J]. J Clin Exp Hepatol, 2025, 15(5): 102580. DOI:10.1016/j.jceh.2025.102580.
[38] Enric R, Puneeta T, Salvador A, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding [J]. Gastroenterology, 2014, 146(2):412-419,e413. DOI: 10.1053/j.gastro.2013.10.018.
[39] David EK, Cristina R, Maja T, et al. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis[J]. Hepatology, 2024,79(5):1180-1211. DOI: 10.1097/HEP.0000000000000647.